Bristol-Myers' Opdivo-Yervoy cocktail slashes kidney cancer death risk by 37%

9th September 2017 Uncategorised 0

Bristol-Myers Squibb smashed doubt about Opdivo and Yervoy’s utility in first-line kidney cancer on Sunday with data showing patients lived longer when treated up front with the combo, rather than with Pfizer’s standard-of-care med, Sutent.

More: Bristol-Myers' Opdivo-Yervoy cocktail slashes kidney cancer death risk by 37%
Source: fierce